AOTMiT: Transparency Council on breast cancer, hemophilia and PTSD, among others

The agenda includes:

1 Prepare a position paper on the evaluation of the drug Wainzua (eplontersen) under drug program B.170. "Treatment of adult patients with stage I or II polyneuropathy in the course of hereditary transthyretin amyloidosis (ICD-10: E85.1)".

2 Prepare an opinion on the introduction of the medicinal product Veyvondi (Vonikog alfa) to the PPZ "National Program for the Treatment of Patients with Hemophilia and Related Hemorrhagic Diathesis for 2024-2028" for the indication: for patients with type 2 and 3 von Willebrand disease.

3 Prepare a position paper to examine the appropriateness of issuing reimbursement approvals for the medicinal product Kygevvi (doxecitine and doxribtimine) for the indication: thymidine kinase deficiency 2.

4 Prepare an opinion on the active substance abemacyclib for the following off-label indication: under the drug program B.9.FM. "Treatment of patients with breast cancer (ICD-10: C50)", for the indication: in combination with hormone therapy for the treatment of adult patients with early-stage breast cancer expressing the hormone receptor and not expressing the type 2 receptor for human epidermal growth factor.

5 Prepare an opinion on the draft health policy program of the local government unit "Health policy program of the Mazovian province in the field of prevention of post-traumatic stress disorder (PTSD)".

6. Prepare an opinion on the draft health policy program of the local government unit ""I see better" Health policy program on early detection of eye defects among children in Lodz".

Source: AOTMiT